MedTrace Logo

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer

NCT02040610 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2019-04-05

No results posted yet for this study

Summary

This study is being proposed to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients. Quality of life outcomes as well as gastrointestinal and genitourinary early and late toxicities will be analyzed and compared to conventional proton therapy regimens. It is thought that this regimen will produce comparable findings and would result in substantial health care cost savings, as well as, be more convenient for patients.

Conditions

Interventions

RADIATION

Hypofractionated Proton Therapy

Sponsors & Collaborators

  • Center for Biomedical Research, LLC

    collaborator OTHER

  • Provision Center for Proton Therapy

    lead OTHER

Principal Investigators

  • J. Ben Wilkinson, M.D. · Provision Center for Proton Therapy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040610 on ClinicalTrials.gov